| 序号 | 专利名 | 申请号 | 申请日 | 公开（公告）号 | 公开（公告）日 | 发明人 |
|---|---|---|---|---|---|---|
| 1 | STABILIZED SOLUBLE PRE-FUSION RSV F POLYPEPTIDES | US14899531 | 2014-06-17 | US20160176932A1 | 2016-06-23 | Johannes P.M. Langedijk; Anders Krarup |
| This disclosure provides stable pre-fusion respiratory syncytial virus (RSV) F polypeptides, immunogenic compositions comprising the polypeptides, and uses thereof for the prevention and/or treatment of RSV infection. | ||||||
| 2 | COMPOSITIONS AND METHODS FOR IMMUNOTHERAPY | US14676255 | 2015-04-01 | US20150342993A1 | 2015-12-03 | Christopher C. Kloss; Michael Sadelain |
| The present invention provides immunoresponsive cells, including T cells, cytotoxic T cells, regulatory T cells, and Natural Killer (NK) cells, expressing at least one of an antigen recognizing receptor and one of a chimeric costimulatory receptor. Methods of using the immunoresponsive cell include those for the treatment of neoplasia and other pathologies where an increase in an antigen-specific immune response is desired. | ||||||
| 3 | Viral Vector Immunogenic Compositions | US13877002 | 2011-09-30 | US20140127258A1 | 2014-05-08 | Simone de Cassan; Alexander Douglas; Simon Draper; Emily Forbes; Anna Goodman; Adrian Hill; Antia Millicic; Arturo Reyes-Sandoval |
| There is provided a composition comprising: (a) a modified vaccinia virus ankara (MVA) vector, wherein said MVA vector comprises a nucleic acid sequence encoding an antigen; and (b) an adjuvant comprising a saponin, or an emulsion. There is also provided a composition comprising: (a) an adenovirus vector, wherein said adenovirus vector comprises a nucleic acid sequence encoding an antigen, and wherein the adenovirus is selected from: a group B adenovirus, a group C adenovirus, and a group E adenovirus; and (b) an adjuvant comprising a saponin, or an emulsion; wherein the group B adenovirus is not an adenovirus 35, the group C adenovirus is not Ad5 having an intact E3 gene region, and the group E adenovirus is not an adenovirus C7. Also provided are corresponding uses of the compositions in medicine. | ||||||
| 4 | INFLUENZA VIRUS POPULATIONS, METHODS OF USE AND METHODS OF MAKING THEREOF | US13721787 | 2012-12-20 | US20130156733A1 | 2013-06-20 | Philip I. Marcus; John M. Ngunjiri; Margaret J. Sekellick; Chang-Won Lee |
| Disclosed herein are live attenuated influenza virus compositions for inducing interferon comprising quantified subpopulations of interferon-inducing particles and defective-interfering particles. The live attenuated influenza virus compositions are particularly useful to induce interferon in an individual having or suspected of having a viral infection. Further, by infecting mammalian and avian cells with the live attenuated influenza virus compositions, the compositions optimized for mammalian or avian species can be selected based on the ratio of defective-interfering particles to interferon-inducing particles. | ||||||
| 5 | 安定化された可溶性融合前ＲＳＶ Ｆポリペプチド | JP2016520435 | 2014-06-17 | JP2016522230A | 2016-07-28 | ペトリュス マリア ランゲデイク ヨハネス; クラルプ アンダース |
| 本発明は、安定な融合前呼吸器合胞体ウイルス(RSV)Fポリペプチド、前記ポリペプチドを含む免疫原性組成物、およびRSV感染を防止および/または処置するためのその使用を提供する。 | ||||||
| 6 | STABILIZED SOLUBLE PRE-FUSION RSV F POLYPEPTIDES | EP14731940.4 | 2014-06-17 | EP3010931A1 | 2016-04-27 | LANGEDIJK, Johannes Petrus Maria; KRARUP, Anders |
| This disclosure provides stable pre-fusion respiratory syncytial virus (RSV) F polypeptides, immunogenic compositions comprising the polypeptides, and uses thereof for the prevention and/or treatment of RSV infection. | ||||||
| 7 | COMPOSITIONS AND METHODS FOR IMMUNOTHERAPY | EP13844468.2 | 2013-10-02 | EP2903637A1 | 2015-08-12 | KLOSS, Christopher C.; SADELAIN, Michel |
| The present invention provides immunoresponsive cells, including T cells, cytotoxic T cells, regulatory T cells, and Natural Killer (NK) cells, expressing at least one of an antigen recognizing receptor and one of a chimeric costimulatory receptor. Methods of using the immunoresponsive cell include those for the treatment of neoplasia and other pathologies where an increase in an antigen-specific immune response is desired. | ||||||
| 8 | VIRAL VECTOR IMMUNOGENIC COMPOSITIONS | EP11764845.1 | 2011-09-30 | EP2621529A2 | 2013-08-07 | DE CASSAN, Simone; DOUGLAS, Alexander; DRAPER, Simon; FORBES, Emily; GOODMAN, Anna; HILL, Adrian; MILICIC, Anita; REYES-SANDOVAL, Arturo |
| There is provided a composition comprising: (a) a modified vaccinia virus ankara (MVA) vector, wherein said MVA vector comprises a nucleic acid sequence encoding an antigen; and (b) an adjuvant comprising a saponin, or an emulsion. There is also provided a composition comprising: (a) an adenovirus vector, wherein said adenovirus vector comprises a nucleic acid sequence encoding an antigen, and wherein the adenovirus is selected from: a group B adenovirus, a group C adenovirus, and a group E adenovirus; and (b) an adjuvant comprising a saponin, or an emulsion; wherein the group B adenovirus is not an adenovirus 35, the group C adenovirus is not Ad5 having an intact E3 gene region, and the group E adenovirus is not an adenovirus C7. Also provided are corresponding uses of the compositions in medicine. | ||||||
| 9 | 免疫療法のための組成物および方法 | JP2018047734 | 2018-03-15 | JP2018108111A | 2018-07-12 | クリストファー シー. クロス; マイケル サデレイン |
| 【課題】前立腺がん、乳がん、B細胞白血病、多発性骨髄腫、および卵巣がんからなる群より選択されるがんに対して、被験体において腫瘍細胞数を減少させ、腫瘍サイズを縮小させ、そして/または腫瘍を根絶するための腫瘍細胞を標的とするT細胞を提供する組成物および方法の提供。 【解決手段】免疫応答細胞であって、a.低親和性で第1の抗原を結合する抗原認識レセプターであって、ここで該第1の抗原への該レセプターの結合は、該免疫応答細胞を活性化させる、抗原認識レセプター;及びb.第2の抗原を結合し、該免疫応答細胞を刺激するキメラ共刺激レセプター(CCR)、を含む、免疫応答細胞。 【選択図】なし |
||||||
| 10 | 免疫療法のための組成物および方法 | JP2015534828 | 2013-10-02 | JP2015535689A | 2015-12-17 | クリストファー シー． クロス，; マイケル サデレイン， |
| 本発明は、抗原認識レセプターのうちの少なくとも1つおよびキメラ共刺激レセプターのうちの1つを発現する免疫応答細胞(T細胞、細胞傷害性T細胞、制御性T細胞、およびナチュラルキラー(NK)細胞が挙げられる)を提供する。上記免疫応答細胞を使用するための方法は、抗原特異的免疫応答の増大が所望される新形成および他の病変の処置のための方法を含む。例えば、免疫応答細胞であって、a.低親和性で第1の抗原を結合する抗原認識レセプターであって、ここで該第1の抗原への該レセプターの結合は、該免疫応答細胞を活性化させる、抗原認識レセプター;およびb.第2の抗原を結合し、該免疫応答細胞を刺激するキメラ共刺激レセプター(CCR)、を含む、免疫応答細胞が提供される。 | ||||||
| 11 | STABILIZED SOLUBLE PRE-FUSION RSV F POLYPEPTIDES | EP14731940.4 | 2014-06-17 | EP3010931B1 | 2018-06-13 | LANGEDIJK, Johannes Petrus Maria; KRARUP, Anders |
| This disclosure provides stable pre-fusion respiratory syncytial virus (RSV) F polypeptides, immunogenic compositions comprising the polypeptides, and uses thereof for the prevention and/or treatment of RSV infection. | ||||||
| 12 | COMPOSITIONS AND METHODS FOR IMMUNOTHERAPY | EP13844468 | 2013-10-02 | EP2903637A4 | 2016-10-19 | KLOSS CHRISTOPHER C; SADELAIN MICHEL |
| The present invention provides immunoresponsive cells, including T cells, cytotoxic T cells, regulatory T cells, and Natural Killer (NK) cells, expressing at least one of an antigen recognizing receptor and one of a chimeric costimulatory receptor. Methods of using the immunoresponsive cell include those for the treatment of neoplasia and other pathologies where an increase in an antigen-specific immune response is desired. | ||||||
| 13 | 안정화된 가용성 예비융합 ＲＳＶ Ｆ 폴리펩타이드 | KR1020167000649 | 2014-06-17 | KR1020160021196A | 2016-02-24 | 랜게드디크,요한페트루스마리아; 크라루프,안드레아 |
| 본발명은안정한예비융합호흡기세포융합바이러스(RSV) F 폴리펩타이드, 상기폴리펩타이드를포함하는면역원성조성물, 및 RSV 감염의예방및/또는치료를위한이들의용도에관한것이다. | ||||||
| 14 | 면역치료용 조성물 및 방법 | KR1020157011160 | 2013-10-02 | KR1020150063145A | 2015-06-08 | 클로스크리스토퍼씨.; 새들레인마이클 |
| 본발명은적어도하나의항원인식수용체및 하나의키메라공자극수용체를발현하는 T 세포, 세포독성 T 세포, 조절 T 세포및 자연살해(NK) 세포를포함하는면역반응성세포를제공한다. 상기면역반응성세포를이용하는방법은항원-특이적면역반응의증가가요구되는신생물및 다른병리의치료방법을포함한다. | ||||||
| 15 | VIRAL VECTOR IMMUNOGENIC COMPOSITIONS | PCT/GB2011051865 | 2011-09-30 | WO2012042279A3 | 2012-07-26 | DE CASSAN SIMONE; DOUGLAS ALEXANDER; DRAPER SIMON; FORBES EMILY; GOODMAN ANNA; HILL ADRIAN; MILICIC ANITA; REYES-SANDOVAL ARTURO |
| There is provided a composition comprising: (a) a modified vaccinia virus ankara (MVA) vector, wherein said MVA vector comprises a nucleic acid sequence encoding an antigen; and (b) an adjuvant comprising a saponin, or an emulsion. There is also provided a composition comprising:(a) an adenovirus vector, wherein said adenovirus vector comprises a nucleic acid sequence encoding an antigen, and wherein the adenovirus is selected from: a group B adenovirus, a group C adenovirus, and a group E adenovirus; and (b) an adjuvant comprising a saponin, or an emulsion; wherein the group B adenovirus is not an adenovirus 35, the group C adenovirus is not Ad5 having an intact E3 gene region, and the group E adenovirus is not an adenovirus C7. Also provided are corresponding uses of the compositions in medicine. | ||||||
QQ群二维码
意见反馈
意见反馈